KCNQ Channel Modulation via Small Molecule Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies are inadequate in modulating KCNQ channel activity to effectively treat aberrant KCNQ channel function associated with epilepsy, deafness, and arrhythmias such as long-QT syndrome and atrial fibrillation, due to incomplete understanding of KCNQ channel structural modeling and conflicting results regarding ATP and PIP2 binding domains.
Innovation Solution
The use of small molecules that bind to specific amino acid sequences of KCNQ channels, including the S2-S3, S4-S5, S6-C-terminal linker domains, and the C-terminal domain, to modulate KCNQ channel activity, thereby enhancing or reducing channel function, and the administration of these molecules to subjects in need to treat associated conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If structural modeling of KCNQ channels is pursued to identify binding domains, then understanding of ATP and PIP2 binding sites improves, but conflicting results in literature indicate incomplete and unreliable structural models
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to bridge the gap between incomplete structural models and functional understanding. These compounds serve as tools to experimentally probe and identify binding domains (such as the S2-S3 linker and C-terminal regions) without relying solely on conflicting computational models, thereby resolving the contradiction between needing structural information and having unreliable models.
2Reliability
If existing treatments are used for KCNQ channel disorders, then treatment of epilepsy, deafness and arrhythmias is attempted, but therapeutic efficacy is insufficient due to inadequate modulation capability
Solution Approach 1:
The patent applies parameter changes by developing small molecule compounds that specifically target and modulate KCNQ channel activity. These compounds alter key parameters such as channel open probability, activation voltage, and current amplitude, enabling precise control of channel function. This provides the adaptability needed to treat different KCNQ-related disorders (epilepsy, deafness, arrhythmias) with tailored modulation strategies, thereby improving therapeutic efficacy.
3Ease of manufacture
If small molecules are designed to bind specific KCNQ channel domains, then targeted modulation of channel activity is achieved, but complexity of identifying correct binding sites increases due to incomplete structural data
Solution Approach 1:
The patent segments the KCNQ channel into distinct functional domains (S2-S3 linker, C-terminal region, transmembrane segments) and develops small molecules that selectively target each segment. This segmentation approach simplifies the drug design process by focusing on specific, functionally important regions rather than attempting to model the entire complex channel structure, thereby reducing the complexity of binding site identification while maintaining targeted modulation capability.
Data Source
AI summary
The present disclosure relates to methods and compositions for modulating the activity of KCNQ channels as a means for reducing the effects of aberrant KCNQ channel function associated with epilepsy, deafness and arrhythmias including but not limited to, Long-QT syndrome (“LQTS”), and atrial fibrillation. The present disclosure also relates to the discovery of certain regions of KCNQ channels that interact with various channel stimulating molecules such as, ATP, and PIP2, as well as KCNQ channel domains that effect voltage dependant channel activation. The disclosure is also directed to the use of small molecules to modulate KCNQ channel activity in a cell. Moreover, the present disclosure relates to the therapeutic effects of treating a subject with modulators of KCNQ channel activity.